Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Operations: 2018-2024

Historic Cash from Operations for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$266.8 million.

  • Phathom Pharmaceuticals' Cash from Operations rose 77.80% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.2 million, marking a year-over-year increase of 8.85%. This contributed to the annual value of -$266.8 million for FY2024, which is 93.90% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Cash from Operations stood at -$266.8 million for FY2024, which was down 93.90% from -$137.6 million recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' Cash from Operations registered a high of -$69.7 million during FY2020, and its lowest value of -$266.8 million during FY2024.
  • Its 3-year average for Cash from Operations is -$183.6 million, with a median of -$146.5 million in 2022.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Cash from Operations tumbled by 113.03% in 2021, and later grew by 6.11% in 2023.
  • Phathom Pharmaceuticals' Cash from Operations (Yearly) stood at -$69.7 million in 2020, then tumbled by 113.03% to -$148.5 million in 2021, then rose by 1.30% to -$146.5 million in 2022, then increased by 6.11% to -$137.6 million in 2023, then plummeted by 93.90% to -$266.8 million in 2024.